RECIST

RECIST
Name	RECIST
Caption	Tumor measurement schematic
Specialty	Oncology
Developed by	European Organization for Research and Treatment of Cancer; Therasse et al. (1999)
First published	2000
Updated	2009

RECIST

RECIST is a standardized set of radiologic response criteria used to assess changes in tumor burden during oncologic therapy. It provides a common language for investigators at institutions such as National Cancer Institute, European Organisation for Research and Treatment of Cancer, and regulatory bodies like U.S. Food and Drug Administration and European Medicines Agency to interpret imaging endpoints in clinical trials. RECIST aims to harmonize measurements across trials conducted by groups including EORTC, SWOG, and cooperative groups affiliated with World Health Organization standards.

Introduction

RECIST defines measurable disease, methods for selecting target lesions, and quantitative thresholds for categorizing response as complete response, partial response, stable disease, or progressive disease for trials overseen by entities such as European Society for Medical Oncology and American Society of Clinical Oncology. The framework influenced trial design in studies led by investigators at Memorial Sloan Kettering Cancer Center, Mayo Clinic, Johns Hopkins Hospital, and within programs funded by National Institutes of Health. RECIST facilitates comparability across landmark trials like those reported in journals associated with New England Journal of Medicine, The Lancet, and Journal of Clinical Oncology.

History and development

Development of RECIST grew from earlier tumor response initiatives including criteria promulgated by the World Health Organization in the 1970s and the efforts of research consortia such as EORTC and North Central Cancer Treatment Group. Key milestones occurred with the 2000 publication led by members affiliated with Institute Gustave Roussy and subsequent collaborative updates published in 2009 by experts connected to Royal Marsden Hospital and academic centers such as University of Oxford and University College London. Regulatory interest from FDA and harmonization work with agencies like International Conference on Harmonisation shaped methodological refinements used in trials sponsored by pharmaceutical companies such as Roche, Pfizer, and Novartis.

Criteria and assessment methods

RECIST specifies measurement of longest diameters on cross-sectional imaging modalities commonly performed at hospitals such as Mayo Clinic and diagnostic centers linked to Massachusetts General Hospital. Assessors select up to five target lesions total (maximum two per organ) and track summed longest diameters to derive response categories used in randomized trials conducted by groups like EORTC and North American Neuroendocrine Tumor Society. The criteria incorporate imaging techniques including computed tomography performed on scanners from manufacturers such as GE Healthcare and Siemens Healthineers, and magnetic resonance imaging protocols used at institutions like Cleveland Clinic. Central review systems managed by academic core labs at MD Anderson Cancer Center often apply RECIST definitions during blinded independent central review to support submissions to agencies including EMA.

Clinical applications

RECIST underpins endpoint definitions in pivotal oncology trials for malignancies treated at centers such as Dana-Farber Cancer Institute and University of Texas MD Anderson Cancer Center. It is commonly applied in trials for solid tumors including those studied in cooperative groups like ALLIANCE and disease-specific networks such as European Lung Cancer Working Party. Pharmaceutical development programs at companies like AstraZeneca and academic investigator-initiated trials at Fred Hutchinson Cancer Center rely on RECIST to quantify tumor shrinkage for efficacy claims and to guide interim analyses reviewed by data monitoring committees often convened with members from American Association for Cancer Research.

Limitations and controversies

RECIST has been criticized for limitations noted by researchers at Memorial Sloan Kettering Cancer Center and methodologists associated with Cochrane Collaboration because linear measurements may not capture complex morphologic changes induced by targeted therapies developed by companies such as Genentech and Bristol Myers Squibb. Challenges arise in assessing tumors with necrosis, cavitation, or atypical response patterns seen with immune checkpoint inhibitors studied in trials led by Yale School of Medicine and Stanford University School of Medicine. Debates involving guideline committees at European Society for Medical Oncology and regulatory scientists at FDA and EMA have addressed issues of pseudoprogression, non-measurable lesions, and the adequacy of thresholds originally proposed in the 2000 and 2009 documents.

Variants and related guidelines

Several adaptations and complementary frameworks have been developed by groups such as Immune-related Response Criteria proponents at UCSF and radiology consortia including Radiological Society of North America. Examples include iRECIST advocated by panels with contributors from ICON plc-linked working groups and modified approaches for specific tumor types produced by specialty societies like European Association for the Study of the Liver for hepatocellular carcinoma and Response Evaluation Criteria in Neuro-Oncology from neuro-oncology centers including MD Anderson Cancer Center. Parallel size- and volume-based systems, plus metabolic criteria from European Organization for Research and Treatment of Cancer's PET working groups and standards promoted by Society of Nuclear Medicine and Molecular Imaging, represent related guidance used alongside RECIST in contemporary oncology research.

Category:Oncology